Investments
564Portfolio Exits
125Funds
28Partners & Customers
6Service Providers
2About Versant Ventures
Versant Ventures is a healthcare investment firm committed to helping entrepreneurs build the healthcare companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $1.9 billion under management and offices in North America and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building.
Want to inform investors similar to Versant Ventures about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Versant Ventures
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Versant Ventures in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Research containing Versant Ventures
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Versant Ventures in 1 CB Insights research brief, most recently on Feb 2, 2021.
Feb 2, 2021
Stealth Startup Funding Surged In 2020Latest Versant Ventures News
Sep 17, 2023
Pierre Fabre Laboratories acquires Vertical Bio AG 14 September 2023 – Pierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer of novel cancer therapies. Vertical Bio was founded by Versant Ventures and was launched out of the firm's Ridgeline Discovery Engine based in Basel, Switzerland. Leveraging Ridgeline's biology capabilities, Vertical Bio advanced VERT-002 through preclinical studies and towards an IND submission. The first-in-human studies are expected to begin in 2024. Walder Wyss advised Versant Ventures on this transaction. The team included Alexander Gutmans (Partner, Corporate/M&A), Lucas Maurer (Associate, Corporate/M&A), Simon Olstein (Associate, Corporate/M&A), Karina Tschon (Senior Associate, Corporate/M&A) and Michelle Bruni (Managing Associate, Corporate/M&A and Tax). Walder Wyss Ltd.
Versant Ventures Investments
564 Investments
Versant Ventures has made 564 investments. Their latest investment was in Tentarix Biotherapeutics as part of their Series B on September 9, 2023.
Versant Ventures Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
9/6/2023 | Series B | Tentarix Biotherapeutics | $35M | No | 2 | |
8/21/2023 | PIPE | Skye Bioscience | $12M | Yes | 5AM Ventures, Undisclosed Investors, and Versant Ventures | 2 |
7/26/2023 | Series A | Nexo Therapeutics | $60M | No | 1 | |
7/11/2023 | Series C | |||||
6/8/2023 | Series A |
Date | 9/6/2023 | 8/21/2023 | 7/26/2023 | 7/11/2023 | 6/8/2023 |
|---|---|---|---|---|---|
Round | Series B | PIPE | Series A | Series C | Series A |
Company | Tentarix Biotherapeutics | Skye Bioscience | Nexo Therapeutics | ||
Amount | $35M | $12M | $60M | ||
New? | No | Yes | No | ||
Co-Investors | 5AM Ventures, Undisclosed Investors, and Versant Ventures | ||||
Sources | 2 | 2 | 1 |
Versant Ventures Portfolio Exits
125 Portfolio Exits
Versant Ventures has 125 portfolio exits. Their latest portfolio exit was RayzeBio on September 15, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
9/15/2023 | IPO | Public | 3 | ||
8/21/2023 | Acquired | 2 | |||
8/8/2023 | Acquired | 4 | |||
Date | 9/15/2023 | 8/21/2023 | 8/8/2023 | ||
|---|---|---|---|---|---|
Exit | IPO | Acquired | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 3 | 2 | 4 |
Versant Ventures Fund History
28 Fund Histories
Versant Ventures has 28 funds, including Versant Venture Capital VIII.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
4/21/2021 | Versant Venture Capital VIII | $560M | 1 | ||
4/21/2021 | Versant Vantage II | $240M | 2 | ||
11/18/2020 | Versant Venture Capital VII | $600M | 3 | ||
8/13/2019 | Versant Voyageurs I | ||||
4/24/2018 | Versant Voyageurs I Feeder |
Closing Date | 4/21/2021 | 4/21/2021 | 11/18/2020 | 8/13/2019 | 4/24/2018 |
|---|---|---|---|---|---|
Fund | Versant Venture Capital VIII | Versant Vantage II | Versant Venture Capital VII | Versant Voyageurs I | Versant Voyageurs I Feeder |
Fund Type | |||||
Status | |||||
Amount | $560M | $240M | $600M | ||
Sources | 1 | 2 | 3 |
Versant Ventures Partners & Customers
6 Partners and customers
Versant Ventures has 6 strategic partners and customers. Versant Ventures recently partnered with AbCellera on July 7, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
7/27/2022 | Licensor | Canada | Versant Ventures and AbCellera Biologics Inc. already have enabled three of the firm 's stealth-stage companies under previous partnerships . | 4 | |
11/30/2021 | Partner | ||||
2/15/2017 | Partner | ||||
12/12/2016 | Partner | ||||
6/23/2014 | Partner |
Date | 7/27/2022 | 11/30/2021 | 2/15/2017 | 12/12/2016 | 6/23/2014 |
|---|---|---|---|---|---|
Type | Licensor | Partner | Partner | Partner | Partner |
Business Partner | |||||
Country | Canada | ||||
News Snippet | Versant Ventures and AbCellera Biologics Inc. already have enabled three of the firm 's stealth-stage companies under previous partnerships . | ||||
Sources | 4 |
Versant Ventures Service Providers
2 Service Providers
Versant Ventures has 2 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Counsel | General Counsel | ||
Service Provider | ||
|---|---|---|
Associated Rounds | ||
Provider Type | Counsel | |
Service Type | General Counsel |
Partnership data by VentureSource
Versant Ventures Team
24 Team Members
Versant Ventures has 24 team members, including current Founder, Managing Director, Brian G Atwood.
Name | Work History | Title | Status |
|---|---|---|---|
Brian G Atwood | Founder, Managing Director | Current | |
Name | Brian G Atwood | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Founder, Managing Director | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
